HIF Inhibition and Emerging Therapeutic Targets in Clear Cell Renal Cell Carcinoma
Canadian Oncology Today · 14.04.2026 · 34-39
DOI: 10.58931/cot.2026.3148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, online erschienen am 14.04.2026. Verfasst von Bharath Gangadharaiah und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau (VHL) pathway, resulting in stabilization of hypoxia-inducible factors (HIFs) and activation of transcriptional programs involved in angiogenesis, metabolism, and tumour survival. This biology established HIF-2α as a rational therapeutic target and led to the development of belzutifan, the first HIF-2 inhibitor to demonstrate randomized clinical benefit in ccRCC. In this review, we summarize the biologic rationale for HIF inhibition in ccRCC, review the key data supporting belzutifan with a focus on the LITESPARK-005, LITESPARK-011, and LITESPARK-022 studies, discuss next-generation HIF-2 inhibitors, including casdatifan, and briefly highlight other emerging therapeutic targets in ccRCC.
Zitieren
APA
Gangadharaiah, B., & Graham, J. (2026). HIF Inhibition and Emerging Therapeutic Targets in Clear Cell Renal Cell Carcinoma. Canadian Oncology Today, 34-39. https://doi.org/10.58931/cot.2026.3148
Vancouver
Gangadharaiah B, Graham J. HIF Inhibition and Emerging Therapeutic Targets in Clear Cell Renal Cell Carcinoma. Canadian Oncology Today. 2026:34-39. doi:10.58931/cot.2026.3148
BibTeX
@article{Gangadharaiah2026,
author = {Gangadharaiah, Bharath and Graham, Jeffrey},
title = {HIF Inhibition and Emerging Therapeutic Targets in Clear Cell Renal Cell Carcinoma},
journal = {Canadian Oncology Today},
year = {2026},
pages = {34--39},
doi = {10.58931/cot.2026.3148}
}
EUVIMED